LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $118.00 at Citizens Jmp

LeMaitre Vascular (NASDAQ:LMAT) had its price target increased by Citizens Jmp from $113.00 to $118.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the medical instruments supplier’s stock. Citizens Jmp’s price target suggests a potential upside of 11.70% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Barrington Research reissued an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Friday, February 20th. Finally, Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Four analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $103.17.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT traded up $14.26 during mid-day trading on Thursday, hitting $105.64. The stock had a trading volume of 191,905 shares, compared to its average volume of 146,258. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $112.65. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 45.17, a PEG ratio of 2.01 and a beta of 0.72. The company’s 50 day simple moving average is $85.98 and its 200 day simple moving average is $88.12.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The firm had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. During the same quarter in the prior year, the company earned $0.49 earnings per share. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities research analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently modified their holdings of LMAT. Vanguard Group Inc. lifted its stake in LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares during the last quarter. First Trust Advisors LP grew its stake in shares of LeMaitre Vascular by 13.4% during the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after buying an additional 111,193 shares during the last quarter. Geneva Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock worth $76,010,000 after buying an additional 51,489 shares in the last quarter. State Street Corp increased its holdings in shares of LeMaitre Vascular by 0.8% during the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after buying an additional 6,130 shares in the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of LeMaitre Vascular by 5.8% in the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after acquiring an additional 40,065 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular News Summary

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat consensus: GAAP EPS $0.68 vs. $0.67 expected and revenue $64.45M vs. $62.98M expected; revenue rose 15.7% year-over-year — underlying growth and margin strength support the rally. MarketBeat: Earnings Report
• Positive Sentiment: Guidance raised: Q1 FY2026 EPS guide of $0.640–0.690 (above consensus $0.620) and FY2026 EPS $2.810–3.010 (vs. consensus $2.610); revenue guides also above estimates — implies management confident in secular growth. Press Release: FY2026 Guidance
• Positive Sentiment: Dividend increase: quarterly payout raised 25% to $0.25/share (ex-dividend March 12, pay March 26), signaling capital-return discipline and confidence in cash flow — supports investor sentiment.
• Neutral Sentiment: Earnings call and analysis available for details on product/market drivers; investors should review management commentary on procedure volumes and M&A. SA: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Coverage/analysis pieces (e.g., Benzinga) summarize expectations and may influence short-term flows but add no new company facts. Benzinga: Earnings Expectations
• Negative Sentiment: Valuation and yield context: LMAT trades at a relatively rich P/E (~46) and a modest dividend yield (~1.1%), which could limit upside if growth slows or guidance is trimmed in future quarters.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.